Company / SG&A Expense
Adaptive Biotechnologies Corp SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$72.7M
FY2025
5-year range
$72.7M / $88.5M
FY2021-FY2025
Trend
-0.1%
vs FY2024
Sector context
#132 of 213
Health Care
What the data says
At $73M, Adaptive Biotechnologies Corp's sg&a expense ranks #82 of 213 in the Health Care sector. SG&A Expense has declined for 3 consecutive years, from $89M in FY2022 to $73M in FY2025.
Based on SEC 10-K filings.
$73M in FY2025 with a 5-year CAGR of +8.0%.
Improved from $84M to $73M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -6.4%
- 5-Year CAGR
- +8.0%
- 10-Year CAGR
- -
Sector benchmark
#82 of 213 in Health CareTop 38% of 213This company $72.7M Sector average $722.3M
▼
-89.9% below sector average
Key checks
Key Insights
- Adaptive Biotechnologies Corp's sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of +8.0%, indicating consistent growth.
- In FY2025, sg&a expense decreased 0.1% year-over-year.
- Ranks #132 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.45 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $72.7M | -0.1% |
| FY2024 | $72.8M | -13.3% |
| FY2023 | $83.9M | -5.2% |
| FY2022 | $88.5M | +18.8% |
| FY2021 | $74.5M | +50.4% |
| FY2020 | $49.5M | +63.3% |
| FY2019 | $30.3M | +48.6% |
| FY2018 | $20.4M | +28.0% |
| FY2017 | $15.9M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026